Trials / Completed
CompletedNCT04590937
A Study in Healthy People to Test Whether BI 730357 Affects How 4 Other Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Taken up in the Body
The Effect of BI 730357 on the Pharmacokinetics of Rosuvastatin, Digoxin, Metformin and Furosemide Given as a Cocktail - an Open-label, Non-randomised, 2-period Fixed-sequence Trial in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main objective of this trial is to investigate the effect of BI 730357 under steady state conditions on the pharmacokinetics of digoxin, furosemide, metformin and rosuvastatin given as a cocktail (Reference, R: cocktail alone; Test T: cocktail given under steady state conditions of BI 730357).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 730357 | Film-coated tablet |
| DRUG | CRESTOR® | Film-coated tablet |
| DRUG | Lenoxin® | Tablet |
| DRUG | MetfoLiquid GeriaSan® | Oral solution |
| DRUG | Lasix® | Oral solution |
Timeline
- Start date
- 2020-10-20
- Primary completion
- 2021-01-11
- Completion
- 2021-01-11
- First posted
- 2020-10-19
- Last updated
- 2023-09-06
- Results posted
- 2023-07-17
Locations
1 site across 1 country: Germany
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04590937. Inclusion in this directory is not an endorsement.